A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Everolimus (Primary)
- Indications Angiomyolipoma; Lymphangioleiomyomatosis; Tuberous sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms EXIST-2
- Sponsors Novartis
- 19 Jul 2018 Results assessing the effect of everolimus on renal function in patients with tuberous sclerosis complex from EXIST-1 and EXIST-2 studies, published in the Nephrology Dialysis Transplantation.
- 10 May 2016 Long-term results of extension study (n=112) presented at the 111th Annual Meeting of the American Urological Association
- 21 Apr 2016 Results (n=119) of pooled analysis of 3 studies (NCT00411619, NCT00789828 and NCT00790400) analysing endocrine and menstrual cycle-related events in females presented at the 68th Annual Meeting of the American Academy of Neurology